Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

FORTREA HOLDINGS INC

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

Scopri i cinque titoli chiave da seguire nel pre-market di oggi, 12 agosto 2024, con focus su risultati e previsioni.

Pre-market: 5 titoli da monitorare oggi, 12 agosto 2024

Fortrea Holdings Inc

American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) reported quarterly losses of $(0.20) per share. This is a 433.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $9.07 million in sales this quarter. This is a 59.16 percent increase over sales of $5.70 million the same period last year.

Earnings

American Shared Hospital Q4 2024 GAAP EPS $(0.20) Down From $0.06 YoY, Sales $9.07M Up From $5.70M YoY

NGVC

Natural Grocers Launches Three New Non-GMO Peruvian Chip Varieties Under Store Brand

Health Care

Management

General

American Shared Hospital Services Appoints Gary Delanois As CEO

"This transaction will strengthen the company's investment grade balance sheet by reducing our borrowings and unlocking the unrecognized value of critical assets," said Glenn Brandt, Chief Financial Officer. "With this transaction, Rogers will have issued an aggregate $9 billion of equity-valued capital since year-end, which is expected to reduce leverage by almost 1 turn."

Rogers to Use C$7B Investment From Blackstone-Led Group To Repay Debt And Boost Balance Sheet

The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/GBX/earnings">closing bell on Monday, April 7.</a>
Analysts expect the Lake Oswego, Oregon-based company to report quarterly earnings at $1.78 per share, up from $1.03 per share in the year-ago period. Greenbrier projects to report quarterly revenue at $898.53 million, compared to $862.7 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, Greenbrier announced a 7% increase to its quarterly dividend.
Greenbrier shares tumbled 9.4% to close at $47.10 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>B of A Securities analyst Ken Hoexter maintained an Underperform rating and raised the price target from $60 to $62 on Jan. 9, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Stephens &amp; Co. analyst Justin Long maintained an Overweight rating and increased the price target from $62 to $65 on April 8, 2024. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying GBX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-1024x591.png" alt="" class="wp-image-856981" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04031446/image-1-10.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Analyst Ratings

Greenbrier Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Under the terms of the transaction, Blackstone will acquire a non-controlling interest in a new Canadian subsidiary of Rogers that will own a minor part of Rogers wireless network.&nbsp;Rogers will maintain full operational control of its network and will include the financial results of the subsidiary in its consolidated financial statements.
 &nbsp;

Rogers Communications Inks C$7B Deal With Blackstone, CPP And Others for 49.9% Stake In New Wireless Subsidiary

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $22 price target.

Price Target

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target

EQUINIX REVERSES EARLY WEAKNESS AFTER ALERT ON NEGATIVE DAY FOR BROAD MARKET
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03201757/Screenshot-2025-04-03-at-4.14.47%E2%80%AFPM-1007x1024.png" alt="" class="wp-image-9720" /></figure>
Equinix, Inc. (EQIX) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:08 AM on April 3rd, a significant trading signal occurred for Equinix, Inc. (EQIX) as it demonstrated a Power Inflow at a price of $789.95. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Equinix&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Equinix&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for EQIX, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:The price at the time of the Power Inflow was $789.95. The returns on the high price post-signal ($809.36) and close price ($801.44) after the Power Inflow are respectively 2.5% and 1.5%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance Not Indicative of Future Results

Equities

WIIM

Technicals

Signals

Equinix Stock Up 2.5% After key Signal, Despite Market Sell-off

The Company expects to receive aggregate gross proceeds of US$9.8 million from the Offering, before deducting underwriting discounts and other related expenses.

IPOs

BLIV

BeLive Holdings Prices IPO Of 2.45M Ordinary Shares At $4.00 Per Share; Shares Expected To Commence Trading On April 4, Under Ticker Symbol 'BLIV'

American Shared Hospital Services Q4 Revenue Rises 59.2% YoY To $9.069M, Exits Quarter With Cash And Equivalents Worth $11.275M

Needham analyst Scott Berg reiterates Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $52 price target.

Reiteration

FIVN

Needham Reiterates Buy on Five9, Maintains $52 Price Target

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $58 price target.

Rosenblatt Maintains Buy on Five9, Maintains $58 Price Target

Top billionaires Elon Musk, Mark Zuckerberg, and Jensen Huang lost nearly $34 billion after the bloodbath on Wall Street on Thursday. Here&#8217;s how much the &#8216;Magnificent 7&#8217; billionaires lost in total.
What Happened: Wall Street witnessed its most brutal trading day in years, with all major U.S. stock indexes experiencing their largest single-day drops on Thursday since the COVID-19 pandemic.
The richest business leaders lost billions of dollars as the stock market declined. Notably, Meta Platforms Inc.&#8216;s founder, chairman, and CEO, Zuckerberg, lost $17.9 billion in a single day, according to Forbes data.
Amazon.com Inc. founder Jeff Bezos saw his net worth plummet by a staggering $16 billion, while Tesla Inc. co-founder and CEO Musk lost $8.7 billion amid the market selloff.
On the other hand, chipmaker Nvidia Corp.&#8216;s founder and CEO, Huang, saw a $7.4 billion change in his net worth, whereas Microsoft Corp. co-founder Bill Gates&#8216; wealth tumbled by $774 million on Thursday.
Alphabet Inc. co-founders Larry Page and Sergey Brin lost $4.9 billion and $4.6 billion, respectively, while the company&#8217;s CEO, Sundar Pichai, saw his net worth decline by $18 million.
Apple Inc. CEO Tim Cook witnessed a loss of $68 million.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>Thursday&#8217;s Performance</td>
<td>Business Leaders</td>
<td>Change In Wealth (In Billion Dollars)</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>-26.40%</td>
<td>-7.81%</td>
<td>Jensen Huang</td>
<td>-7.4</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>-16.67%</td>
<td>-9.25%</td>
<td>Tim Cook</td>
<td>-0.068</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>-10.86%</td>
<td>-2.36%</td>
<td>Bill Gates</td>
<td>-0.774</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-18.99%</td>
<td>-8.98%</td>
<td>Jeff Bezos</td>
<td>-16</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-19.93%</td>
<td>-3.92%</td>
<td>Sundar Pichai</td>
<td>-0.018</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>-11.28%</td>
<td>-8.96%</td>
<td>Mark Zuckerberg</td>
<td>-17.9</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>-5.47%</td>
<td>-29.53%</td>
<td>Elon Musk</td>
<td>-8.7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Forbes</figcaption></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44643368/donald-trump-says-market-is-going-to-boom-claiming-6-7-trillion-worth-of-inflows-will-come">Donald Trump Says &#8216;Market Is Going To Boom,&#8217; Claiming &#8216;$6-7 Trillion&#8217; Worth Of Inflows Will Come After The Worst Selloff Since 2020</a>
Why It Matters: The Dow Jones endured its fifth-worst day in history, shedding 1,679 points. It was Dow and S&amp;P 500&#8217;s worst trading day since June 2020. Meanwhile, the Nasdaq had its most significant single-day decline since March 2020.
Citing the necessity to rectify the United States' trade deficit, Trump utilized a 1977 statute to officially declare a trade emergency, subsequently introducing new tariffs on Wednesday.
He imposed a blanket 10% tariff on all trading partners and levied more duties on the countries he described as "bad actors".
It is worth noting that China, Vietnam, Cambodia, and Sri Lanka are subject to the most severe tariffs, whereas Canada and Mexico were exempted from &#8220;Liberation Day&#8221; tariffs.
Benchmark indices are in the correction zone. The S&amp;P 500 fell 12.22% from its Feb. 19th peak, the Nasdaq 100 dropped 16.65% from its 52-week high, approaching the bear market territory, and the Dow was down 10.05% as of Thursday.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 2.30% to $525.78, while the QQQ declined 2.52% to $439.32, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44642131/volatility-gauge-vix-surges-to-an-8-month-high-more-fear-more-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Volatility Gauge Vix Surges To An 8-Month High: ‘More Fear Equals More Opportunity,' Says Analyst</a></li>
</ul>
Image via Shutterstock

Tech

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Elon Musk, Mark Zuckerberg And Jensen Huang See $34 Billion Wiped Out In A Single Day: Here's How Much Other 'Magnificent 7' Billionaires Lost After Trump's Liberation Day

IREN

IREN March 2025 Bitcoin Mined 533 BTC, Up From 459 BTC In Feb; Revenue $45.3M, Up From $43.9M In Feb

HC Wainwright &amp; Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and lowers the price target from $14 to $12.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $12

NTRB

Nutriband Inc. Signs Associate Partnership Deal With Charlotte FC To Boost Brand Visibility, Promote AI Tape

Rosenblatt analyst Mike Genovese upgrades Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from Neutral to Buy and lowers the price target from $115 to $85.

Upgrades

COHR

Rosenblatt Upgrades Coherent to Buy, Lowers Price Target to $85

AerCap Closes Q1 2025 With 112 Lease Deals, $1.5B Financing, And $558M Share Buyback

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Macro Economic Events

Economics

China Earlier Announced 34% Tariff On All U.S. Imports Starting April 10 In Response To U.S.Tariffs Imposed By President Trump

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

Legal

FORTREA ALERT: Bragar Eagel & Squire, P.C. is Investigating Fortrea Holdings Inc. on Behalf of Fortrea Stockholders and Encourages Investors to Contact the Firm

Small Cap

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Fortrea Holdings Inc. - FTRE

IBTA

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Fortrea Holdings

Notizie

Ultime notizie per Fortrea Holdings (NASDAQ:FTRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO